tiprankstipranks
Advertisement
Advertisement
Dr. Reddy’s Launches India’s First DCGI-Approved Generic Semaglutide Obeda for Type 2 Diabetes
PremiumCompany AnnouncementsDr. Reddy’s Launches India’s First DCGI-Approved Generic Semaglutide Obeda for Type 2 Diabetes
27d ago
Dr. Reddy’s Faces GST Penalty Orders for FY 2019–22, Sees No Material Impact
Premium
Company Announcements
Dr. Reddy’s Faces GST Penalty Orders for FY 2019–22, Sees No Material Impact
1M ago
Dr. Reddy’s Flags Phase III Setback as Immutep Halts Key Lung Cancer Trial
Premium
Company Announcements
Dr. Reddy’s Flags Phase III Setback as Immutep Halts Key Lung Cancer Trial
1M ago
Dr. Reddy’s Says SEC Ends FCPA Probe Without Recommending Enforcement Action
PremiumCompany AnnouncementsDr. Reddy’s Says SEC Ends FCPA Probe Without Recommending Enforcement Action
2M ago
Dr. Reddy’s reports FDA acceptance to review Abatacept BLA
Premium
The Fly
Dr. Reddy’s reports FDA acceptance to review Abatacept BLA
2M ago
Dr. Reddy’s Buys Progynova HRT Brands in India to Bolster Gynecology Portfolio
Premium
Company Announcements
Dr. Reddy’s Buys Progynova HRT Brands in India to Bolster Gynecology Portfolio
2M ago
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
PremiumThe FlyCoya Therapeutics to sell 2.522M shares at $4.40 in private placement
3M ago
Dr. Reddy’s Q3 Earnings Call: Growth Amid Margin Strain
Premium
Company Announcements
Dr. Reddy’s Q3 Earnings Call: Growth Amid Margin Strain
3M ago
Dr. Reddy’s Russian Subsidiary Faces VAT Reclassification Penalty Deemed Immaterial
Premium
Company Announcements
Dr. Reddy’s Russian Subsidiary Faces VAT Reclassification Penalty Deemed Immaterial
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100